Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2022 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022

Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders Together, Will Ring the Nasdaq Opening Bell to...
February 17, 2022 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022

CORAL GABLES, Fla., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on developing...
February 07, 2022 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update

2021 Total Revenues Estimated at $141 Million, Representing 18% YoY Growth Forecast 2022 Total Revenues of Between $195 Million and $205 Million, Representing YoY Growth of 38% to 45% Recently...
February 03, 2022 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid

CORAL GABLES, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
January 28, 2022 13:46 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst

CORAL GABLES, Fla., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
January 10, 2022 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing

CORAL GABLES, Fla., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
January 04, 2022 07:30 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences

CORAL GABLES, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
December 06, 2021 07:00 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan

CORAL GABLES, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
November 15, 2021 16:15 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

CORAL GABLES, Fla., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
November 09, 2021 16:14 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results

Continued Strong Financial and Operational Performance in the Third Quarter 2021FIRDAPSE® Revenue of $35.9 Million Increased 23.1% Compared to Third Quarter 2020Plans to Seek to Expand the U.S....

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right